Health care stocks were narrowly lower, with the NYSE Health Care Index falling 0.3% while the SPDR Health Care Select Sector ETF also was down 0.3%. The Nasdaq Biotechnology index, however, was climbing 0.2%. In company news, Tricida (TCDA) plunged 30% after the US Food and Drug Administration rejected the company's appeal to the agency last year turning down the new drug application for its veverimer drug candidate to treat metabolic acidosis in patients with chronic kidney disease.